Many global biotech companies view China as a post-hoc commercial market, considering the country only in later stages of clinical development. | Leading biotechs are rethinking China’s role in global ...

Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has ...

AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis ...

BioXcel Therapeutics has filed for bankruptcy and lined up a deal for T | BioXcel Therapeutics has filed for bankruptcy and ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the ...

While mRNA may be back in the headlines courtesy of Moderna and Merck & Co.'s phase 3 cancer vaccine success, new research ...

Studying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists ...

Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its ...

After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the ...

Roche has won an extended clearance by the FDA for its tests that can find patients eligible to use Jazz Pharmaceuticals’ ...

Flagship Pioneering’s ProFound Therapeutics is keeping its string of high-profile partnerships going, forging a pact with the ...